Recently, the World Health Organisation granted emergency use listing to Covaxin, enabling countries to expedite their regulatory approval to import and administer doses.The jab has also received emergency use authorisations in several countries with applications in process in more than 50 countries worldwide.Bharat Biotech has partnered with Ocugen to obtain approvals for Covaxin in the United States and Canada.With more than 150 million doses manufactured, supplied, and with an excellent safety and efficacy profile, Covaxin is a major contributor to the global fight against the COVID-19 pandemic, the statement said.Covaxin is currently being evaluated in controlled clinical trials in children 2-18 years of age, with results available during Q4 2021.Bharat Biotech is poised to achieve its goal of an annualised capacity of about 1.0 billion doses of the jab by the end of 2021.
Source link
